Agency removes boxed warnings after new scientific review
By BCNews Staff Writer
The U.S. Food and Drug Administration has approved updated safety labeling for six menopausal hormone therapy (HRT) products, removing boxed warnings related to cardiovascular disease, breast cancer and probable dementia. Federal health officials say the changes reflect updated scientific evidence and aim to give women clearer, more accurate information about treatment options.
The revisions follow an FDA review launched in late 2025. Twenty‑nine drug manufacturers were asked to submit updated labels, and this first group of approvals includes products across all major categories of menopausal hormone therapy: systemic combination therapy, estrogen‑alone therapy, progestogen‑alone therapy for women.
Health and Human Services Secretary Robert F. Kennedy, Jr. said the decision underscores the importance of correcting outdated risk statements as research evolves. FDA Commissioner Marty Makary, M.D., M.P.H., added that the changes support women in making informed decisions about therapies that can significantly improve quality of life.
Menopause symptoms, such as hot flashes, night sweats, vaginal dryness, urinary changes and bone loss can last for years. Although multiple FDA‑approved hormone therapies are available, only a small percentage of eligible women use them. Studies show that women who begin HRT within 10 years of menopause, typically before age 60, may see reduced mortality and fewer fractures.fda
This action will help women, in consultation with their health care providers, make clearer and more informed decisions about managing menopause symptoms, and the FDA says the updated labels will further support those conversations by outlining the benefits and risks of treatment in a more accurate, evidence‑based way.
©2026 bcdollarsaver.com. All rights reserved.
Be the first to comment